Trials / Unknown
UnknownNCT06234670
Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,200 (estimated)
- Sponsor
- Wenwen Wang · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To research risk factors for recurrence of uterine fibroids and build a prediction model of recurrence of uterine fibroids to facilitate the early detection as well as the early intervention for patients who are prone to recur.
Detailed description
Uterine fibroids are the most common benign tumors of female reproductive organs during childbearing age. With the emphasis on fertility preservation and the pursuit of the physical integrity, about 46% of patients prefer the conservative surgery which preserves the uterus. However, the high recurrence rate of uterine fibroids after conservative surgery does cause formidable clinical problems. According to the literature, the recurrence rate is about 11.7% at one year after myomectomy and would increase steadily. At the eighth year of myomectomy, the recurrence rate is as high as 84.4%. During the long-term follow-up, about one-third of patients eventually require reoperation. Recurrence not only leads to the recurrence of fibroid-related symptoms such as anemia, abdominal and pelvic pain, frequent urination and urgency, abnormal stool, etc., but also increases the burden of economic and national medical insurance, besides, it even causes serious problems such as psychological disorders, infertility, adverse pregnancy outcomes and malignant transformation, which affecting physical and mental health as well as destroying family happiness and threatening national population security.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervertion | This study is a retrospective observational study without intervention. |
Timeline
- Start date
- 2024-01-25
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2024-01-31
- Last updated
- 2024-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06234670. Inclusion in this directory is not an endorsement.